Literature DB >> 9234178

Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma.

R Handgretinger1, J Greil, U Schürmann, P Lang, O Gonzalez-Ramella, I Schmidt, R Führer, D Niethammer, T Klingebiel.   

Abstract

Peripheral stem cells were mobilized and collected in 20 children with stage 4 neuroblastoma. A total of 37 leukaphereses were performed in the 20 patients. The mean number of collected cells was 5.6 +/- 2.4 x 10(8)/kg (range 1.9-10.5), and the number of collected CD34+ progenitors was 6.1 +/- 6.3 x 10(6)/kg (range 0.75-21.7). CD34-positive selection was performed using the CellPro method. Of the adsorbed cells, 42 +/- 20% (range 4.3-76.6) stained positively for CD34, and the number of positively selected CD34+ cells was 2.0 +/- 1.9 x 10(6)/kg (range 0.09-7.1). The mean recovery of CD34+ cells was 36 +/- 20% (range 6-67). For detection of contaminating neuroblastoma cells before and after CD34-positive selection, a murine antidisialoganglioside GD2 antibody (14.G2a) was used, followed by the alkaline phosphatase antialkaline phosphatase (APAAP) method. Before the positive selection, various numbers of contaminating neuroblastoma cells were found in the leukaphereses of 7 patients. After positive selection, neuroblastoma cells were still detectable in all 7 patients, with a mean log depletion of tumor cells of 1.41 +/- 0.45 (range 0.69-2.13). In 1 patient, contaminating neuroblastoma cells were found only after CD34-positive selection. In 15 of the 20 patients, high-dose chemotherapy was performed, and positively selected CD34+ cells were reinfused in 12 patients. In 10 of these, the mean time to reach > 0.5 x 10(9)/L granulocytes was 12.3 +/- 1.7 days (range 10-16). One patient died at day 7 due to sepsis, and in 1 patient the backup was given at day 15. Because of the low number of collected CD34+ cells, 3 patients were grafted with a combination of unmanipulated PBSC and CD34+ progenitors. In summary, we have shown that positive selection of peripheral CD34+ progenitors is feasible in pediatric patients. However, strategies to improve the recovery of the CD34+ cells and the purging efficacy of this method (i.e., higher enrichment of CD34+ cells, combination of positive and negative selection methods) should be evaluated further.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9234178     DOI: 10.1089/scd.1.1997.6.235

Source DB:  PubMed          Journal:  J Hematother        ISSN: 1061-6128


  6 in total

Review 1.  Micrometastases in neuroblastoma: are they clinically important?

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

2.  Optimized processing of growth factor mobilized peripheral blood CD34+ products by counterflow centrifugal elutriation.

Authors:  Chy-Anh Tran; Monica Torres-Coronado; Agnes Gardner; Angel Gu; Hieu Vu; Anitha Rao; Lan-Feng Cao; Amira Ahmed; David Digiusto
Journal:  Stem Cells Transl Med       Date:  2012-05-08       Impact factor: 6.940

Review 3.  Neuroblastoma: current drug therapy recommendations as part of the total treatment approach.

Authors:  F Berthold; B Hero
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

4.  Neuroblastoma: treatment outcome after incomplete resection of primary tumors.

Authors:  Suk-Bae Moon; Kwi-Won Park; Sung-Eun Jung; Woong-Jae Youn
Journal:  Pediatr Surg Int       Date:  2009-07-21       Impact factor: 1.827

5.  Label-free neuroblastoma cell separation from hematopoietic progenitor cell products using acoustophoresis - towards cell processing of complex biological samples.

Authors:  Franziska Olm; Anke Urbansky; Josefina H Dykes; Thomas Laurell; Stefan Scheding
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

6.  Retrospective analysis of peripheral blood stem cell transplantation for the treatment of high-risk neuroblastoma.

Authors:  Eun Kyung Kim; Hyoung Jin Kang; Jeong Ah Park; Hyoung Soo Choi; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2007-09       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.